Glassman Wealth Services increased its position in shares of Eli Lilly and Company (NYSE:LLY – Get Rating) by 5.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,332 shares of the company’s stock after acquiring an additional 71 shares during the quarter. Glassman Wealth Services’ holdings in Eli Lilly and were worth $381,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently modified their holdings of the company. AllSquare Wealth Management LLC acquired a new position in Eli Lilly and in the fourth quarter valued at about $28,000. HWG Holdings LP acquired a new position in Eli Lilly and in the fourth quarter valued at about $28,000. Icapital Wealth LLC acquired a new position in Eli Lilly and in the first quarter valued at about $28,000. Leverty Financial Group LLC acquired a new position in Eli Lilly and in the fourth quarter valued at about $29,000. Finally, FSB Premier Wealth Management Inc. acquired a new position in Eli Lilly and in the fourth quarter valued at about $30,000. 82.75% of the stock is currently owned by institutional investors and hedge funds.
In other Eli Lilly and news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and stock in a transaction on Wednesday, June 1st. The stock was sold at an average price of $313.44, for a total value of $313,440.00. Following the completion of the transaction, the chief accounting officer now directly owns 6,274 shares of the company’s stock, valued at approximately $1,966,522.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 2,500 shares of Eli Lilly and stock in a transaction on Wednesday, March 30th. The shares were sold at an average price of $292.03, for a total value of $730,075.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 848,630 shares of company stock valued at $259,239,945. 0.12% of the stock is currently owned by insiders.
Eli Lilly and (NYSE:LLY – Get Rating) last released its quarterly earnings results on Thursday, April 28th. The company reported $2.62 earnings per share for the quarter, topping the consensus estimate of $2.32 by $0.30. The business had revenue of $7.81 billion during the quarter, compared to analysts’ expectations of $7.29 billion. Eli Lilly and had a return on equity of 97.58% and a net margin of 20.90%. The firm’s revenue for the quarter was up 14.8% compared to the same quarter last year. During the same period last year, the firm posted $1.87 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 8.27 EPS for the current year.
The company also recently declared a quarterly dividend, which was paid on Friday, June 10th. Investors of record on Monday, May 16th were issued a dividend of $0.98 per share. The ex-dividend date was Friday, May 13th. This represents a $3.92 annualized dividend and a yield of 1.27%. Eli Lilly and’s payout ratio is currently 58.07%.
LLY has been the topic of a number of research analyst reports. StockNews.com lowered Eli Lilly and from a “strong-buy” rating to a “buy” rating in a research report on Thursday. The Goldman Sachs Group raised their price target on Eli Lilly and from $234.00 to $264.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 12th. Morgan Stanley raised their price target on Eli Lilly and from $364.00 to $369.00 in a research report on Friday, April 29th. Mizuho raised their price target on Eli Lilly and from $315.00 to $356.00 in a research report on Monday, May 2nd. Finally, SVB Leerink initiated coverage on Eli Lilly and in a research report on Monday, May 23rd. They set an “outperform” rating and a $341.00 price target on the stock. Three analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $311.00.
About Eli Lilly and (Get Rating)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
- Get a free copy of the StockNews.com research report on Eli Lilly and (LLY)
- It’s A Comfortable Time To Buy Steelcase
- Worthington’s Posts Strong Results, But Earnings Fall On One-Off Adjustments
- A Tasty Entry Point Into Darden Restaurants International
- NXP Semiconductors: Strong Earnings & New Microcontrollers for Electric Vehicles
- Lithium Stocks Are Offering Unprecedented Opportunity To Investors
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.